Ann: APIRx Acquisition Presentation, page-16

Yes with the portfolio we now have, I d be very very surprised if we don’t have big pharmaceutical interest before too long.

I believe we are well past the “we have big potential stage.”

Results from all trials have been very solid, if OSA results turn out to be from lowest dose, then it’s going to get very interesting.

I d be very surprised if 216a doesn’t work atleast as well on human brains….

Compass also had some positive results for their GAD trial so things are looking very good when you add the APIRx drugs to the mix.

400 Billion dollar addressable market is mind boggling.